Evaluation of Safety and Efficacy of the Apyx™ Device for the Repair of Pelvic Organ Prolapse (POP)

Pelvic Organ Prolapse Clinical Trial

Official title:

Evaluation of Safety and Efficacy of the Apyx™ Device for the Repair of Pelvic Organ Prolapse (POP)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03991455
• Other study ID #: 1806019328
• Status: Completed
• Phase: N/A
• Start date: October 25, 2019
• Est. completion date: May 1, 2022

Study information

• Verified date: July 2022
• Source: Escala Medical LTD
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to further evaluate this minimally invasive SSLF technique with respect to safety, clinical effectiveness, and patient satisfaction. The procedure will be performed in women electing to undergo surgical repair of their prolapse who wish to preserve their uterus, and will be evaluated using standardized measures and questionnaires.

Description:

This study will evaluate sacrospinous ligament fixation using an incision-free technique - a technique that was developed with the goal of offering a technically simple, safe, and effective alternative to surgical prolapse repair procedures. When compared to previously reported SSLF methods, this technique has undergone novel modifications with the intent of maximizing efficacy and minimizing invasiveness. First, each sacrospinous ligament is approached trans-vaginally using a small diameter, low profile needle as the delivery platform for the anchoring unit. Secondly, the suspension is bilateral, thus maintaining vaginal length and width without deviation or narrowing of the vagina as might occur with a traditional (unilateral) sacrospinous repair. And third, using bio-degradable sutures and a securing element that stabilizes the fixation as opposed to performing an incision in the vaginal wall for suturing enables an incision-free procedure leaving the vagina free of any device after a period of several weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: May 1, 2022
• Est. primary completion date: May 1, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

Women with prolapse electing to undergo reconstructive vaginal surgery for primary uterovaginal prolapse, who wish to enroll in this trial of an incision-free prolapse repair technique, after being familiarized with the suspected benefits and risks of the procedure.

• Ages 18-90 years old

• POP-Q Stage 2 or greater with an apical support defect, also defined as uterovaginal prolapse

• Desire of uterine preservation

• Patient is willing to return for follow-up evaluation and questionnaire completion at 3 months, 6 months, and 12 months, in addition to routine postoperative standard of care.

• English fluency

Exclusion Criteria:

• Previous vaginal, abdominal, or laparoscopic repair for pelvic organ prolapse

• Prior hysterectomy

• Known allergy to Nitinol / Stainless Steel / Polydioxanone.

• Suspected uterine pathology, including malignancy.

• History of chronic pelvic pain, interstitial cystitis or fibromyalgia.

• Women diagnosed with symptomatic uterine fibroids, cervical elongation or hypertrophy, abnormal uterine or vaginal bleeding.

• History of Pelvic Inflammatory Disease (PID)

• Prior pelvic radiation therapy or malignancy.

• Diagnosis of reproductive tract anomalies.

• Pregnant or lactating women.

• Participation in another trial

• Inability to provide informed consent for study enrollment

• PI's subjective assessment that study procedure will not plausibly correct patient pelvic organ prolapse symptoms due to anatomic considerations

Related Conditions & MeSH terms

• Pelvic Organ Prolapse
• Prolapse

Intervention

Device:
• Apyx device
The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system.

Locations

Country	Name	City	State
Israel	Rambam Medical Center	Haifa

Sponsors (1)

Lead Sponsor	Collaborator
Escala Medical LTD

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in PFDI-20 Prolapse Subscale (POPDI-6) score	Pelvic Floor Disability Index (PFDI-20) includes 20 questions are rated from 0 to 4, with 0 is no present of distress and 4 is the highest of symptom scale. Pelvic Floor Disability Index distress index is a subscale of the first 6 questions of the above scale	6 months
Secondary	Objective success rate	POP-Q points Ba less than -1 and C less than -½ TVL	6 months
Secondary	Change in PFDI-20	Pelvic Floor Disability Index (PFDI-20) includes 20 questions are rated from 0 to 4, with 0 is no present of distress and 4 is the highest of symptom scale	at baseline 3 months, 6 months, and 12 months compared to preoperative
Secondary	Change in PISQ-12 scores	The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire -12 (PISQ-12) includes question for estimation of sexual function for women with POP urinary incontinence and or fecal incontinence	at baseline 3 months, 6 months, and 12 months compared to preoperative
Secondary	PGI-I	Patient Global Impression of Improvement include one question which describes how the patient evaluates the post surgery improvement with a scale of 1 to 7. 1 is very much better and 7 is very much worse	3 months, 6 months, and 12 months
Secondary	Unanticipated Device-related Serious Adverse Event rate	Unanticipated Device-related Serious Adverse Event rate	at intervals of 2 weeks, 3 months, 6 months, and 12 months